Weymouth

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. The study aims to assess whether this combination can help reduce cardiovascular risks compared to a placebo with empagliflozin. This Phase III trial involves adults with these conditions who are already receiving treatment for them. Participants are randomly assigned to one of two groups. One group takes vicadrostat and empagliflozin tablets daily, while the other group takes placebo tablets that look like vicadrostat but have no active medicine, alongside empagliflozin. Treatment lasts from two and a half years up to four years and three months. All participants continue their usual medications for diabetes, blood pressure, and heart disease during the study. Throughout the study, lasting up to four years and three months, participants visit the study site regularly for health checks and blood samples. Doctors monitor cardiovascular events and any side effects experienced. The main outcome measured is the time until the first cardiovascular death or heart failure event. Other health indicators like blood pressure and kidney function are also tracked to understand the effects of the treatment combination.

Researchers are evaluating a new blood test called Avantect to detect pancreatic cancer early in people aged 50 to 84 who were recently diagnosed with type 2 diabetes. Pancreatic cancer is often deadly because it is usually found late. This study aims to see if the Avantect test can find signs of cancer sooner, allowing for earlier treatment and better chances of survival. The study is interventional and includes a large group of participants recruited from general practices over three years. Participants will be randomly assigned to one of two groups the intervention arm or the control arm. Those in the intervention arm will have their blood samples tested with the Avantect test quickly, and if cancer markers are found, they will be informed and offered imaging scans like MRI or CT to check for pancreatic cancer. The control group will have their blood samples stored for possible future testing but will receive standard diabetes care. Blood samples and health outcomes will be tracked for three years. Each participant will attend three study visits over 12 months, providing blood samples and completing anxiety questionnaires. Researchers will monitor cancer diagnosis and mortality through registries for three years after consent. They will evaluate the tests sensitivity, specificity, and ability to detect cancer early enough for surgery. The study also measures predictive values and cancer resectability. This design helps understand the tests potential to improve pancreatic cancer detection in people with new diabetes diagnoses.